Ophthalmologica highlightsTuesday, October 2, 2018
Volume 240, Issue 2
Surgical optionsTuesday, October 2, 2018
Surgeons now have a range of safe and successful surgical options available for the management of primary retinal detachments
nAMD treatment shows promiseTuesday, October 2, 2018
Topical integrin inhibitor shows potential therapeutic results in early trial
Cataract surgery riskSunday, September 23, 2018
What is the risk of cataract surgery in the diabetic patient?
New concepts and treatments for diabetesSunday, September 23, 2018
Discussion on key issues of diabetes regarding complications of the disease and side effects of common treatments.
Reducing myopia progressionSunday, September 23, 2018
Pharmacological Prophylaxis of Myopia discussed at 36th Congress of the ESCRS
EURETINA Race Run in Prater ParkSunday, September 23, 2018
TORRENTIAL rain did not deter the dozens of ophthalmologists, scientists and exhibitors who turned out at dawn yesterday to take part in the Retina Race 2018.
Anti-vegf therapyFriday, September 21, 2018
Bridging the gap between clinical trials and real-world outcomes
Anti-VEGF agents have revolutionised the treatment of neovascular age-related macular degeneration
EURETINA comes of ageFriday, September 21, 2018
This year marks a real coming of age for the European Society of Retina Specialists, says society president Sebastian Wolf
Achievements and challenges of current anti-VEGF therapyFriday, September 21, 2018
Anti-VEGF agents have revolutionised the treatment of neovascular age-related macular degeneration, significantly reducing AMD-associated blindness and visual impairment in the process, according to Ursula Schmidt-Erfurth MD, PhD, at a special session on the EURETINA Guidelines for Management of Retinal Disease yesterday. Highlighting the achievements and challenges of current anti-VEGF therapy, Dr Schmidt-Erfurth said that intravitreal […]